ultimo

  • InfiRay Releases World's 1st 8 Micron Thermal Camera Detector

    Yantai, China, June 9, 2021 - (ACN Newswire) - InfiRay has developed the world's 1st 8 micron uncooled thermal camera detector, with a large array (1920 x 1080) and core technologies including a low noise readout circuit, high uniformity VOx film, sub-wavelength optical absorption structure, and small pixel self-heating effect compensation. A higher spatial resolution has been achieved and moving
  • BYD Builds One-millionth New Energy Passenger Car

    First 100 pure-electric BYD Tang SUVs head to Norway with plans to deliver 1500 cars in 2021
  • 【中意首席外交官】文化战略合作全面开启——王云仙

    王云仙,河北人,1958年生,党员,毕业于北京大学和中国政法大学,被中纪委方正出版社聘为高级艺术顾问。现为中国著名书画家,中国书画家联谊会会员,中国书画家联谊会艺创中心主任,中国书画家联谊会新文艺群体书画家工作委员会特聘书画艺术家、会员、理事、副秘书长,中国民族建筑研究会书画艺术专业委员客座教授,中国楹联学会书法艺术研究会副秘书长,中国国土书画研究院执行院长,中国互联网联盟副主编,CCTV特别推荐艺术名家,中国楹联学会书法艺术研究会副主席。
  • China Eastern Airlines ottiene risultati notevoli nella riduzione di emissioni di carbonio e nel perseguimento di uno sviluppo sostenibile

    China Eastern Airlines (China Eastern) ha risparmiato più di 600.000 tonnellate di olio combustibile e ridotto le emissioni di carbonio di circa due milioni di tonnellate nel 2020, grazie ai suoi sforzi per migliorare l'efficienza operativa e promuovere lo sviluppo verde negli ultimi anni, secondo l'ultimo rapporto sulla responsabilità sociale d’impresa (RSI).
  • 《问鼎全球高端 领创璀璨未来》2021年引领全球各界巅峰人物——周和林

    周和林 1950年生于上海,祖籍浙江镇海。学生时代即习书法美术,1984年参加上海中国画院美术书法进修班,师承胡问遂,钱茂生等名师,曾获得“ 上海市职工书法篆刻展”一等奖,“神龙杯”全国青少年书法大赛园丁奖等。作品入编《上海书画家篆刻名典》,1984年由赵冷月,钱茂生介绍加入上海书法家协会,原为上海市少年宫,宜川学区艺术学校书法教师,现为上海东方书画院画师、中华卫视艺术风采栏目艺木会员、中国书画家联谊会新文艺群体书画家工作委员会委员、现在上海同欣进修学校书法兼职教师,民建会艺专委副主席.中国楹联书研会常务理事,新文艺报副编辑。
  • Pecron S1500: The Most Compact Portable Power Station Is Launching On Indiegogo

    Pecron, an under-the-radar brand specialized in portable power source and outdoor energy solutions, is launching its latest model S1500: the most compact portable power station on Indiegogo.
  • China e Brasil celebram a saída do primeiro Skyrail da linha de produção, em Shenzen, na China

    Em 08 de abril a BYD comemorou um novo marco, com seu veículo SkyRail Bahia saindo da linha de produção, em Shenzhen, na China. O SkyRail Bahia, localizado na cidade de Salvador, é a primeira linha SkyRail do mundo parcialmente construída acima do mar.
  • 【中意首席外交官】文化战略合作全面开启——陈一源

    陈一源,字泉灵,号乔仁。四川成都人,中西文化研究独立学者,社会活动家。长于书法、诗词、文化评论与长寿养生;其文学作品散见于各大网络以及报刊杂志。在学术研究方面主张“思人所未思,言人所未言”;倡导“智慧人生”,平生喜欢游历,博览群书,广交天下朋友。
  • Ecco come il lavoro di riduzione della povertà in Cina contribuisce al mondo

    ​A partire dalla riforma e dall’apertura, oltre 770 milioni di abitanti della Cina rurale che vivono al di sotto della soglia di povertà sono stati aiutati a migliorare le proprie condizioni di vita, per un totale che ammonta a oltre il 70% di quello globale nel corso dello stesso periodo secondo gli standard internazionali di povertà della Banca Mondiale, come si evince da un white paper sulla ri
  • The Undervalued Enterprise in the Shadow of Wikipedia, Quora, and MOOC

    Featuring websites such as Wikipedia, Quora, and MOOC, and their Chinese equivalents Baidu Baike (百度百科), Zhihu (知乎), and Dedao (得到), respectively, the online knowledge economy has spawned enterprises that make our lives more convenient.

Link amichevole

Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29     OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Disconoscimento: questo articolo è stato ristampato da altri supporti e ha lo scopo di trasmettere più informazioni. Tutte le risorse di questo sito sono raccolte su Internet e lo scopo della condivisione è per l'apprendimento e il riferimento di tutti. In caso di violazione del copyright o della proprietà intellettuale, lasciaci un messaggio.
Torna all'inizio
© Diritto d'autore 2009-2020 Rete di notizie cinese      Contattaci   SiteMap